Динамика факторов риска сахарного диабета 2 типа и сердечно-сосудистых заболеваний у больных с абдоминальным типом ожирения

1. Бутрова С. А. Метаболический синдром: патогенез, клиника, диагностика, подходы к лечению. РМЖ. - 2001.- № 2 (9). - c. 56-60.

2. Дедов И.И., Сунцов Ю.И., Кудрякова С.В. Эпидемиология сахарного диабета. Сахарный диабет. Руководство для врачей. Авт. Дедов И.И., Шестакова М.В. - М. - Универсум паблишинг 2003; 75-93.

3. Науменкова И.В. Клинико-диагностические аспекты инсулинорезистентности у больных сахарным диабетом 2 типа на инсулинотерапии. Автореферат дис. канд. мед. наук. - М. 2002

4. Boello O, Zamboni M. Visceral obesity and metabolic syndrome. Obes Rev 2000; 1: 47-56.

5. Clinician's Manual on Total Risk Management. A guide to prevention of Coronary Heart Disease. Science Press Ltd and Society of Cardiology 2000.

6. Mattews D, Hosker J, Rudenski A et al. Homeostasis model assessment: insulin resistance and ®-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.

7. Filipovsky J, Ducimeti_re P, Bernadette D, Richard LJ. Abdominal body mass distri- bution and elevated blood pressure are associated with increased risk of death from cardiovascular diseases and cancer in middle-aged men. The results of a 15-to 20- year follow-up in the Paris prospective study I. Int J Obes Relat Metab Disord 1993; 17: 197-203.

8. Friedwald W, Levy R, Fredricson D. Estimation of the concentration of low-density- lipoprotein cholesterol in plasma, without use of the preparative ultra-centrifuge. Clinical Chem 1972; 18: 499-502.

9. Gillum R, Mussolino M, Madans J. Body fat distribution, obesity, overweight and stroke incidence in women and men: the NHANES I Epidemic Follow-up Study. Int J Obes Relat Metab Disord 2001; 25: 628-638.

10. Hube F, Hauner H. The role of TNF alpha in adipocyte tissue: prevention of weight gain at the expense of insulin resistance? Horm Metab Res 1999; 31: 626-631

11. Li L, Lonnqvist F, Luthman H, Arner P. Phenotypic characterisation of the Trp64Arg polymorphism in the beta 3-adreergic receptor gene in normal weight and obese subjects. Diabetologia 1996; 39: 857-860

12. Paolisso G, Taglanonte M, De Lucia D et al. ACE gene polymorphism and in-sulin action in older and healthy centenarians. J Am Geriartr Soc 2001; 49 (5): Abstract: 610-614

13. Panahloo A, Andres G, Mohamed-Ali V et al. The insertion allele of the ACE gene I/D polymorphism a candidate gene for insulin resistance? Circulation 1995; 15; 92 (12): Abstract, 3390-3393.

14. Pedersen O. Genetics of insulin resistance. Exp Clin Endocrinol Diab 1999; 107: 113..-1..1.8. .

15. Pyorala K, Sovalainen E, Kaukola S, Haapakoski J. Plasma insulin as coronary heart disease risk factor: Relationship to other risk factors and predictive during 9 1/2 year follow-up of the Helsinki Policeman Study population. Acta Med Scan 1985; 701 (Suppl): 38-52.

16. Tai E, Corella D, Wilson L et al. Association between the PPARA L162V polymorphism and plasma lipid levels. Interactions with the apoE, apoC3 and LPL LOCI: the Framingham Offspring Study. Atherosclerosis 2001;Vol 2: 33.

17. Third Report of the National Cholesterol Education Progam (NCEP) Expert Panel on Detection, Evaluation and treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH Publication 2001; 5. N 01-3670.

18. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a Who consultation on obesity. World Health Organization: Geneva 1997; 218-219.